Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Acquired by Wealth Alliance

Wealth Alliance increased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 9.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,053 shares of the company’s stock after acquiring an additional 95 shares during the quarter. Wealth Alliance’s holdings in Medpace were worth $323,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of MEDP. Contravisory Investment Management Inc. bought a new stake in Medpace in the fourth quarter valued at about $26,000. RiverPark Advisors LLC bought a new stake in Medpace in the fourth quarter valued at about $26,000. McGlone Suttner Wealth Management Inc. bought a new stake in Medpace in the fourth quarter valued at about $33,000. FinTrust Capital Advisors LLC bought a new stake in Medpace in the third quarter valued at about $30,000. Finally, Altshuler Shaham Ltd bought a new stake in Medpace in the fourth quarter valued at about $27,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on MEDP shares. Deutsche Bank Aktiengesellschaft started coverage on Medpace in a report on Monday, March 18th. They issued a “hold” rating and a $395.00 price objective for the company. Robert W. Baird upped their target price on Medpace from $312.00 to $408.00 and gave the company an “outperform” rating in a report on Wednesday, February 14th. StockNews.com lowered Medpace from a “buy” rating to a “hold” rating in a report on Saturday, March 23rd. Finally, UBS Group raised Medpace from a “neutral” rating to a “buy” rating and upped their target price for the company from $282.00 to $452.00 in a report on Thursday, February 15th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $382.00.

Medpace Trading Down 2.1 %

Shares of NASDAQ MEDP opened at $374.32 on Friday. The stock has a 50 day simple moving average of $394.87 and a 200-day simple moving average of $319.06. The company has a market cap of $11.60 billion, a PE ratio of 42.15, a P/E/G ratio of 2.02 and a beta of 1.38. Medpace Holdings, Inc. has a 12-month low of $185.43 and a 12-month high of $419.42.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 12th. The company reported $2.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.22 by $0.24. The business had revenue of $498.40 million during the quarter, compared to the consensus estimate of $498.72 million. Medpace had a return on equity of 63.98% and a net margin of 15.00%. The business’s revenue was up 26.5% on a year-over-year basis. During the same period in the previous year, the firm posted $2.12 earnings per share. Sell-side analysts forecast that Medpace Holdings, Inc. will post 10.53 earnings per share for the current fiscal year.

Insider Transactions at Medpace

In other Medpace news, CEO August J. Troendle sold 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total value of $41,298,000.00. Following the completion of the sale, the chief executive officer now directly owns 4,833,019 shares in the company, valued at $1,995,940,186.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Medpace news, CEO August J. Troendle sold 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total value of $41,298,000.00. Following the completion of the sale, the chief executive officer now directly owns 4,833,019 shares in the company, valued at $1,995,940,186.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ashley M. Keating sold 250 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $409.87, for a total value of $102,467.50. Following the completion of the sale, the director now owns 250 shares of the company’s stock, valued at $102,467.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 189,340 shares of company stock worth $76,651,647. Company insiders own 20.30% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.